SIRPA and cancer: Recently, pharmaceutical communities have shifted their attention to the development of new anti-cancer medicines that target innate immunity checkpoints, such as the immune checkpoint of macrophages: a cluster of differentiation (CD) 47/signal regulatory protein alpha (SIRPα) pathway.